ZENO MANAGEMENT, INC

Biotech

Novel ERK inhibitor molecules for KRAS-mutant pancreatic cancer treatment

Grants
$1.9M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
40
1 granted · 39 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma$1,060,799
Federal grantDepartment of Health and Human Services · Phase II · Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma$856,578
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2388Avalo Therapeutics—$182M
2389MOCKV SOLUTIONS INC.——
2390SERPIN PHARMA, LLC——
2391ZENO MANAGEMENT, INC——
2392CH3 BIOSYSTEMS, LLC——
2393Autifony Therapeutics——
2394EXARCA PHARMACEUTICALS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 40
  • Alteration Of F-box And Wd Repeat Domain Containing 7 (FBXW7) Gene As A Predictive Biomarker For Treating Cancer With WEE1 Inhibitorsapplication
  • Solid Forms Of A WEE1 Inhibitorapplication
  • Homologous Recombination Repair Deficiency (hrd) As A Predictive Biomarker For Treating Cancer With WEE1 Inhibitorsapplication
  • Intermittent Dosing Regimen For Azenosertib In Treating Cancerapplication
  • Use Of Cyclin E1 Status As A Predictive Biomarker For Treating Cancer With WEE1 Inhibitorsapplication
  • Immunoconjugates And Methodsgranted
  • Macrocyclic Compoundsapplication
  • Macrocyclic Compoundsapplication
  • WEE1 Inhibitor Combination Therapyapplication
  • Alteration Of F-box And Wd Repeat Domain Containing 7 (FBXW7) Gene As A Predictive Biomarker For Treating Cancer With WEE1 Inhibitorsapplication
  • Bi-cyclic Pyrimidine Compounds, Methods And Uses Thereofapplication
  • Solid Forms Of A WEE1 Inhibitorapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.